Actively Recruiting
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
Led by The First Affiliated Hospital of Soochow University · Updated on 2025-11-21
43
Participants Needed
1
Research Sites
198 weeks
Total Duration
On this page
Sponsors
T
The First Affiliated Hospital of Soochow University
Lead Sponsor
J
Jiangsu HengRui Medicine Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to evaluate the efficacy and safety of PD-1 inhibitor, Azacitidine, and low-dose DLI in AML relapse After allogeneic hematopoietic stem cell transplantation
CONDITIONS
Official Title
PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of AML relapse after allogeneic hematopoietic stem cell transplantation
- Adequate organ function
- Able to understand and sign informed consent
- Age 18 to 60 years old
- Negative pregnancy test for females of childbearing potential within one week prior to treatment
- Use of highly effective contraception during the study and for at least 90 days after last treatment dose for females of childbearing potential and sexually active males
- ECOG performance status 0 or 1
- Known HLA-matched donor without contraindications to donate
- Life expectancy greater than 3 months
You will not qualify if you...
- Diagnosis of another malignant disease
- Suspected or proven acute or chronic graft-versus-host disease (GVHD)
- Proven central nervous system leukemia
- Prior treatment with anti-PD-1, anti-PD-L1, or donor lymphocyte infusion
- HLA loss positive
- Known active viral infections including HIV, hepatitis B or C, or COVID-19
- Uncontrolled systemic fungal, bacterial, or viral infection
- Known or suspected hypersensitivity to PD-1 inhibitors or azacitidine
- Participation in another clinical study within the last 3 months
- Any serious medical or psychiatric illness that may interfere with study completion based on investigator's opinion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215006
Actively Recruiting
Research Team
S
Sheng-Li Xue, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here